← Back to Search

Anti-metabolites

Panitumumab for Breast Cancer

Phase 2
Waitlist Available
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before each cycle of panitumumab, nab-paclitaxel and carboplatin (pnc) & fluorouracil, epirubicin and cyclophosphamide (fec) until 30 days after the last dose of drug, an average of 8 months, unless the participant withdraw consent.
Awards & highlights

Study Summary

This trial is testing the efficacy of a combination chemo regimen for the treatment of inflammatory breast cancer.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before each cycle of panitumumab, nab-paclitaxel and carboplatin (pnc) & fluorouracil, epirubicin and cyclophosphamide (fec) until 30 days after the last dose of drug, an average of 8 months, unless the participant withdraw consent.
This trial's timeline: 3 weeks for screening, Varies for treatment, and before each cycle of panitumumab, nab-paclitaxel and carboplatin (pnc) & fluorouracil, epirubicin and cyclophosphamide (fec) until 30 days after the last dose of drug, an average of 8 months, unless the participant withdraw consent. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants That Achieved Pathologic Complete Response (CR)
Secondary outcome measures
Number of Participants With Treatment-related Adverse Events (AEs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: PNC + FECExperimental Treatment6 Interventions
PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and FEC = 5-fluorouracil, epirubicin, and cyclophosphamide
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6670
5-Fluorouracil
2012
Completed Phase 3
~7800
Panitumumab
2020
Completed Phase 3
~6490
Cyclophosphamide
1995
Completed Phase 3
~3770
Nab-paclitaxel
2014
Completed Phase 3
~2030
Epirubicin
2012
Completed Phase 4
~19470

Find a Location

Who is running the clinical trial?

Celgene CorporationIndustry Sponsor
444 Previous Clinical Trials
58,189 Total Patients Enrolled
15 Trials studying Breast Cancer
678 Patients Enrolled for Breast Cancer
M.D. Anderson Cancer CenterLead Sponsor
2,973 Previous Clinical Trials
1,789,274 Total Patients Enrolled
147 Trials studying Breast Cancer
63,239 Patients Enrolled for Breast Cancer
AmgenIndustry Sponsor
1,371 Previous Clinical Trials
1,378,059 Total Patients Enrolled
44 Trials studying Breast Cancer
79,099 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
JAMA OncologyJournal
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients with Primary Her2-negative Inflammatory Breast Cancer
Matsuda, Naoko, Xiaoping Wang, Bora Lim, Savitri Krishnamurthy, Ricardo H. Alvarez, Jie S. Willey, Charla A. Parker, et al.. 2018. “Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients with Primary Her2-negative Inflammatory Breast Cancer”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2018.1436.
clinicaltrials.govStudy
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
2010. "Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01036087.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top